Literature DB >> 16012047

RANKing intracellular signaling in osteoclasts.

Xu Feng1.   

Abstract

RANKL plays a pivotal role in the differentiation, function and survival of osteoclasts, the principal bone-resorbing cells. RANKL exerts the effects by binding RANK, the receptor activator of NF-kappaB, in osteoclasts and its precursors. Upon binding RANKL, RANK activates six major signaling pathways: NFATc1, NF-kappaB, Akt/PKB, JNK, ERK and p38, which play distinct roles in osteoclast differentiation, function and survival. Recent studies have not only provided more insights into RANK signaling but have also revealed that several factors, including INF-gamma, IFN-beta, and ITAM-activated costimulatory signals, regulate osteoclastogenesis via direct crosstalk with RANK signaling. It was recently shown that RANK contains three functional motifs capable of mediating osteoclastogenesis. Moreover, although both IFN-gamma and IFN-beta inhibit osteoclastogenesis, they exert the inhibitory effects by distinct mechanisms. Whereas IFN-gamma has been shown to block osteoclastogenesis by promoting degradation of TRAF6, IFN-beta inhibits osteoclastogenesis by down-regulating c-fos expression. In contrast, the ITAM-activated costimulatory signals positively regulate osteoclastogenesis by mediating the activation of NFATc1 through two ITAM-harboring adaptors: FcRgamma and DAP12. This review is focused on discussing the current understanding of RANK signaling and signaling crosstalk between RANK and the various factors in osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012047     DOI: 10.1080/15216540500137669

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  69 in total

1.  Modeled microgravity and hindlimb unloading sensitize osteoclast precursors to RANKL-mediated osteoclastogenesis.

Authors:  Ritu Saxena; George Pan; Erik D Dohm; Jay M McDonald
Journal:  J Bone Miner Metab       Date:  2010-06-30       Impact factor: 2.626

2.  Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.

Authors:  J Frantzias; J G Logan; P Mollat; A Sparatore; P Del Soldato; S H Ralston; A I Idris
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1).

Authors:  Zhihong Chen; Lingkai Su; Qingan Xu; Jenny Katz; Suzanne M Michalek; Mingwen Fan; Xu Feng; Ping Zhang
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

4.  Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.

Authors:  Angela C Hirbe; Jessica Rubin; Ozge Uluçkan; Elizabeth A Morgan; Mark C Eagleton; Julie L Prior; David Piwnica-Worms; Katherine N Weilbaecher
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

5.  Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.

Authors:  Z J Zhai; H W Li; G W Liu; X H Qu; B Tian; W Yan; Z Lin; T T Tang; A Qin; K R Dai
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Identification of miR-708-5p in peripheral blood monocytes: Potential marker for postmenopausal osteoporosis in Mexican-Mestizo population.

Authors:  Aldo H De-La-Cruz-Montoya; Eric G Ramírez-Salazar; Mayeli M Martínez-Aguilar; Pablo M González-de-la-Rosa; Manuel Quiterio; Cei Abreu-Goodger; Jorge Salmerón; Rafael Velázquez-Cruz
Journal:  Exp Biol Med (Maywood)       Date:  2018-10-15

Review 7.  Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Authors:  Joel Jules; Jason W Ashley; Xu Feng
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

8.  Ameloblastin modulates osteoclastogenesis through the integrin/ERK pathway.

Authors:  Xuanyu Lu; Yoshihiro Ito; Phimon Atsawasuwan; Smit Dangaria; Xiulin Yan; Tuojiang Wu; Carla A Evans; Xianghong Luan
Journal:  Bone       Date:  2013-02-04       Impact factor: 4.398

9.  Notch signaling promotes osteoclast maturation and resorptive activity.

Authors:  Jason W Ashley; Jaimo Ahn; Kurt D Hankenson
Journal:  J Cell Biochem       Date:  2015-11       Impact factor: 4.429

10.  Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.

Authors:  Enrico M Messalli; Cono Scaffa
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.